Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Convidecia vs Pfizer mRNA as Second Booster for COVID-19
NCT05517642Phase 3Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ad5-ncov in coronavirus disease 2019 (COVID-19), sponsored by CanSino Biologics Inc.. Started Sep 2022; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05517642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517642.